Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OCRX's Cash to Debt is ranked higher than
77% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. OCRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OCRX' s 10-Year Cash to Debt Range
Min: 0.68  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.94
OCRX's Equity to Asset is ranked higher than
91% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OCRX: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
OCRX' s 10-Year Equity to Asset Range
Min: -1.09  Med: 0.59 Max: 0.96
Current: 0.94
-1.09
0.96
F-Score: 3
Z-Score: 10.83
M-Score: -1.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7996.02
OCRX's Operating margin (%) is ranked lower than
92% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. OCRX: -7996.02 )
Ranked among companies with meaningful Operating margin (%) only.
OCRX' s 10-Year Operating margin (%) Range
Min: -18034.12  Med: -3770.24 Max: -63.42
Current: -7996.02
-18034.12
-63.42
Net-margin (%) -7954.43
OCRX's Net-margin (%) is ranked lower than
92% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. OCRX: -7954.43 )
Ranked among companies with meaningful Net-margin (%) only.
OCRX' s 10-Year Net-margin (%) Range
Min: -20604.71  Med: -3822.91 Max: -85.5
Current: -7954.43
-20604.71
-85.5
ROE (%) -56.87
OCRX's ROE (%) is ranked lower than
66% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. OCRX: -56.87 )
Ranked among companies with meaningful ROE (%) only.
OCRX' s 10-Year ROE (%) Range
Min: -236.08  Med: -142.63 Max: -49.17
Current: -56.87
-236.08
-49.17
ROA (%) -53.55
OCRX's ROA (%) is ranked lower than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. OCRX: -53.55 )
Ranked among companies with meaningful ROA (%) only.
OCRX' s 10-Year ROA (%) Range
Min: -87.61  Med: -54.63 Max: -15.31
Current: -53.55
-87.61
-15.31
ROC (Joel Greenblatt) (%) -42223.30
OCRX's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. OCRX: -42223.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46351.52  Med: -2161.38 Max: -526.49
Current: -42223.3
-46351.52
-526.49
Revenue Growth (3Y)(%) -85.60
OCRX's Revenue Growth (3Y)(%) is ranked lower than
89% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. OCRX: -85.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -48.80 Max: -85.6
Current: -85.6
EBITDA Growth (3Y)(%) -53.20
OCRX's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. OCRX: -53.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -41.10 Max: -53.2
Current: -53.2
EPS Growth (3Y)(%) -54.20
OCRX's EPS Growth (3Y)(%) is ranked lower than
95% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. OCRX: -54.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -42.05 Max: -54.2
Current: -54.2
» OCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OCRX Guru Trades in Q2 2014

Jim Simons 63,749 sh (+72.07%)
» More
Q3 2014

OCRX Guru Trades in Q3 2014

Jim Simons 38,149 sh (-40.16%)
» More
Q4 2014

OCRX Guru Trades in Q4 2014

Jim Simons 12,549 sh (-67.11%)
» More
Q1 2015

OCRX Guru Trades in Q1 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Ocera Therapeutics Inc

Three Insider Buys at 52-Week Lows
Over the past month three companies have reported insider buys as their price hits or nears 52-week lows. Looking at insider buys while they’re trading at low prices can offer an excellent time to buy into a company or further your research on the company. Peter Lynch once offered that insiders will sell their shares in a company for many reasons, but they will only invest it if they think that the share price will rise.

Read more...

Ratios

vs
industry
vs
history
P/B 1.75
OCRX's P/B is ranked higher than
86% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. OCRX: 1.75 )
Ranked among companies with meaningful P/B only.
OCRX' s 10-Year P/B Range
Min: 0.98  Med: 2.22 Max: 10.49
Current: 1.75
0.98
10.49
P/S 220.21
OCRX's P/S is ranked lower than
86% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. OCRX: 220.21 )
Ranked among companies with meaningful P/S only.
OCRX' s 10-Year P/S Range
Min: 0.06  Med: 6.98 Max: 794
Current: 220.21
0.06
794
EV-to-EBIT -1.15
OCRX's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. OCRX: -1.15 )
Ranked among companies with meaningful EV-to-EBIT only.
OCRX' s 10-Year EV-to-EBIT Range
Min: -19.2  Med: -1.70 Max: 1.1
Current: -1.15
-19.2
1.1
Current Ratio 14.91
OCRX's Current Ratio is ranked higher than
85% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. OCRX: 14.91 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s 10-Year Current Ratio Range
Min: 0.62  Med: 4.58 Max: 21.99
Current: 14.91
0.62
21.99
Quick Ratio 14.91
OCRX's Quick Ratio is ranked higher than
86% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OCRX: 14.91 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s 10-Year Quick Ratio Range
Min: 0.62  Med: 4.58 Max: 21.99
Current: 14.91
0.62
21.99
Days Sales Outstanding 34.60
OCRX's Days Sales Outstanding is ranked higher than
75% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. OCRX: 34.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCRX' s 10-Year Days Sales Outstanding Range
Min: 23.55  Med: 114.91 Max: 399.35
Current: 34.6
23.55
399.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.84
OCRX's Price/Net Cash is ranked higher than
94% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. OCRX: 1.84 )
Ranked among companies with meaningful Price/Net Cash only.
OCRX' s 10-Year Price/Net Cash Range
Min: 1.54  Med: 3.41 Max: 10.42
Current: 1.84
1.54
10.42
Price/Net Current Asset Value 1.81
OCRX's Price/Net Current Asset Value is ranked higher than
94% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. OCRX: 1.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.35  Med: 3.05 Max: 8.97
Current: 1.81
1.35
8.97
Price/Tangible Book 1.71
OCRX's Price/Tangible Book is ranked higher than
88% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. OCRX: 1.71 )
Ranked among companies with meaningful Price/Tangible Book only.
OCRX' s 10-Year Price/Tangible Book Range
Min: 1.24  Med: 2.90 Max: 7.99
Current: 1.71
1.24
7.99
Price/Median PS Value 54.29
OCRX's Price/Median PS Value is ranked lower than
99% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. OCRX: 54.29 )
Ranked among companies with meaningful Price/Median PS Value only.
OCRX' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 0.85 Max: 91
Current: 54.29
0.01
91
Earnings Yield (Greenblatt) (%) -80.70
OCRX's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OCRX: -80.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -103.28  Med: 119.75 Max: 790
Current: -80.7
-103.28
790

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TY1.Germany,
Ocera Therapeutics Inc was incorporated in Delaware on December 20, 2004. The Company is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy or HE. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. In pre-clinical studies, OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia, brain ammonia and intracranial pressure in a second animal model of acute liver failure. OCR-002 has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant HE in patients with acute liver failure and acute-on-chronic liver disease. OCR-002 has also been granted orphan drug designation in the European Union for the treatment of acute liver failure. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 22 2015
Ocera Therapeutics to Present at the JMP Securities Life Sciences Conference Jun 16 2015
Ocera Therapeutics to Present at the JMP Securities Life Sciences Conference Jun 16 2015
Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman Jun 08 2015
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference May 29 2015
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference May 29 2015
OCERA THERAPEUTICS, INC. Financials May 20 2015
10-Q for Ocera Therapeutics, Inc. May 09 2015
OCERA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 07 2015
10-K for Ocera Therapeutics, Inc. May 05 2015
Ocera CEO to be Honored at the 17th Annual American Liver Foundation's Salute to Excellence Awards... May 04 2015
Ocera CEO to be Honored at the 17th Annual American Liver Foundation's Salute to Excellence Awards... May 04 2015
Ocera Therapeutics Announces Change in Executive Team May 04 2015
Ocera Therapeutics Announces Change in Executive Team May 04 2015
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 04 2015
Ocera reports 1Q loss Apr 30 2015
Ocera reports 1Q loss Apr 30 2015
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results Apr 30 2015
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2015
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK